Show simple item record

dc.contributor.authorOlmos, D
dc.contributor.authorTan, DSW
dc.contributor.authorJones, RL
dc.contributor.authorJudson, IR
dc.date.accessioned2018-06-28T13:13:06Z
dc.date.issued2010-05
dc.identifier.citationCancer journal (Sudbury, Mass.), 2010, 16 (3), pp. 183 - 194
dc.identifier.issn1528-9117
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1963
dc.identifier.eissn1540-336X
dc.identifier.doi10.1097/ppo.0b013e3181dbebf9
dc.description.abstractTwo decades have elapsed since insulin-like growth factor-1 receptor (IGF-1R) signaling was initially implicated in sarcoma biology to the first clinical experience of IGF-1R blockade in sarcoma. During these 21 years, the IGF pathway and its key mediator IGF-1R have been implicated in the genesis, growth, proliferation, metastasis, and resistance to conventional treatment in several sarcoma subtypes. In addition, IGF-1R has been validated, both in vitro and in vivo, as a target for the treatment of sarcoma. Several radiologic and clinical responses to IGF-1R monoclonal antibodies have been reported in Ewing sarcoma patients enrolled in early clinical studies. Furthermore, these therapies were well tolerated, and thus far severe toxicity has been rare. The early clinical evidence of antitumor activity has supported the initiation of various phase II clinical trials in Ewing and other sarcoma subtypes, the results of which are eagerly awaited, as well as studies assessing IGF-1R monoclonal antibodies in combination with traditional cytotoxics or other targeted therapies. Despite these encouraging results, not all patients benefit from IGF-1R inhibition and consequently there is an urgent need for the identification of predictive markers of response.
dc.formatPrint
dc.format.extent183 - 194
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectSarcoma
dc.subjectReceptor, IGF Type 1
dc.subjectAntibodies, Monoclonal
dc.subjectClinical Trials as Topic
dc.titleBiological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside.
dc.typeJournal Article
rioxxterms.versionofrecord10.1097/ppo.0b013e3181dbebf9
rioxxterms.licenseref.startdate2010-05
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCancer journal (Sudbury, Mass.)
pubs.issue3
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume16
pubs.embargo.termsNot known
icr.researchteamSarcoma Clinical Trials (R Jones)en_US
dc.contributor.icrauthorJudson, Ianen
dc.contributor.icrauthorJones, Robinen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record